Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

Max Yano, Jennie Rachel Lance, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4302.

https://doi.org/10.1182/blood-2019-127620

Published: 2019

Journal Articles

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Jennie Rachel Lance, Max Yano, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4303.

https://doi.org/10.1182/blood-2019-131034

Published: 2019

Journal Articles

Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells

Sohaila Mohamed Khalil, Swagata Goswami, MSc, Xiaokui Mo, PhD MAS, Natarajan Muthusamy, DVM,PhD

Blood (2019) 134 (Supplement_1): 3977.

https://doi.org/10.1182/blood-2019-129224

Published: 2019

Journal Articles

Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model

Joseph Thomas Greene, BS, Rahul Ramaswamy, Mary K McKenna, BS, Rajeswaran Mani, DVM,PhD, Frank Frissora, MS, Ronni Wasmuth, BS, Minh Tran, BS, Xiaokui Mo, PhD MAS, Carlo M. Croce, MD, Vivek Rangnekar, PhD, John C. Byrd, MD, Subbarao Bondada, PhD, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1223.

https://doi.org/10.1182/blood.V130.Suppl_1.1223.1223

Published: 2017

Journal Articles

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM,PhD, Xiaokui Mo, PhD MAS, Pearlly S. Yan, PhD, Michael B Broe, PhD, Ralf Bundschuh, PhD, Larry State Beaver, Kevan Zapolnik, BS, Zhiliang Xie, Donna Bucci, David M. Lucas, PhD, Allison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B. Klisovic, MD, Ching-Shih Chen, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MDMBBS, Natarajan Muthusamy, DVM,PhD

Blood (2017) 130 (Supplement 1): 1247.

https://doi.org/10.1182/blood.V130.Suppl_1.1247.1247

Published: 2017

Journal Articles

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

Swagata Goswami, MS, Rajeswaran Mani, DVM PhD, Chi-Ling Chiang, MS, Frank W Frissora, M.S., Xiaokui Mo, PhD MAS, Zhiliang Xie, Donna Bucci, Amber Gordon, MLS, David M. Lucas, PhD, William Blum, MD, Alison R. Walker, MD MPH, Alice S. Mims, MD MSCR, Rebecca B Klisovic, MD, Ching-Shih Chen, PhD, Robert J Lee, PhD, John C. Byrd, MD, Mitch A. Phelps, PhD, Sumithira Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2748.

https://doi.org/10.1182/blood.V128.22.2748.2748

Published: 2016

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

Deborah M Stephens, DO, Kyle A. Beckwith, PhD, Priscilla Do, BS, Carolyn Cheney, BS, Xiaokui Mo, PhD MAS, Karilyn Larkin, MD, Jeffrey Jones, MD MPH, Farrukh T. Awan, Laura Grosmaire, PhD, Randy Jones, PhD, Julie DiPaolo, PhD, Stacey Tannheimer, Karl-Heinz Heider, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 2767.

https://doi.org/10.1182/blood.V128.22.2767.2767

Published: 2016

Journal Articles

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Rajeswaran Mani, DVM PhD, Swagata Goswami, MS, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, PhD MAS, Amber Gordon, MLS, Donna Bucci, David Lucas, PhD, Christopher L. Brooks, PhD, Alison R. Walker, MD MPH, William Blum, MD, John C. Byrd, MD, Gerard Lozanski, MD, Sumithra Vasu, MBBS, Natarajan Muthusamy, DVM, PhD

Blood (2016) 128 (22): 580.

https://doi.org/10.1182/blood.V128.22.580.580

Published: 2016

Journal Articles

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Priscilla Do, BS, Kyle A. Beckwith, PhD, Larry Beaver, Brittany G. Griffin, Xiaokui Mo, PhD MAS, Jeffrey Jones, MD MPH, Erin K. Hertlein, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3221.

https://doi.org/10.1182/blood.V128.22.3221.3221

Published: 2016

Journal Articles

Effects of the Btk Inhibitor Ibrutinib on Monocyte Responses to Antibodies

Li Ren, Amanda Campbell, Shalini Gautam, Huiqing Fang, Kavin Fatehchand, Andrew Stiff, Payal Mehta, Xiaokui Mo, PhD MAS, Xuexun Fang, John C. Byrd, MD, William Carson, Jonathan P. Butchar, PhD, Susheela Tridandapani, PhD

Blood (2015) 126 (23): 1017.

https://doi.org/10.1182/blood.V126.23.1017.1017

Published: 2015

Journal Articles

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Deborah M Stephens, DO, Kyle A Beckwith, B.S., Carolyn Cheney, B.S, Xiaokui Mo, PhD MAS, Joseph M Flynn, D.O., MPH, Jeffrey A. Jones, MD, Kami J. Maddocks, MD, Karl-Heinz Heider, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2014) 124 (21): 4681.

https://doi.org/10.1182/blood.V124.21.4681.4681

Published: 2014

Journal Articles

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Rajeswaran Mani, DVM, Yicheng Mao, PhD, Frank W Frissora, M.S., Chi-ling Chiang, Jiang Wang, Yuan Zhao, Yun Wu, Bo Yu, Ph.D., Ribai Yan, Xiaokui Mo, PhD, Sivasubramanian Baskar, PhD, Christoph Rader, Ph.D., Mitch A. Phelps, PhD, Robert J. Lee, Ph.D, Ching-Shih Chen, PhD, James Lee, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2013) 122 (21): 4168.

https://doi.org/10.1182/blood.V122.21.4168.4168

Published: 2013

Journal Articles

Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia

Tasneem Motiwala, PhD, Satavisha Roy, Shujun Liu, Ph.D, Sebastian Schwind, MD, Rainer Claus, MD, Xiaokui Mo, PhD, Ramiro Garzon, MD, Hartmut Dohner, MD, Konstanze Dohner, MD, PhD, David Jarjoura, PhD, Christoph Plass, PhD, Guido Marcucci, MD, Samson T. Jacob, PhD

Blood (2012) 120 (21): 1322.

https://doi.org/10.1182/blood.V120.21.1322.1322

Published: 2012

Journal Articles

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Kyle A Beckwith, B.S., Frank W Frissora, M.S., Matthew R Stefanovski, B.S., Jutta Deckert, Ph.D., Carlo M Croce, M.D., Xiaokui Mo, PhD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D

Blood (2012) 120 (21): 188.

https://doi.org/10.1182/blood.V120.21.188.188

Published: 2012

Journal Articles

Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties,

Sarwish Rafiq, MS, Jonathan P. Butchar, PhD, Carolyn Cheney, Xiaokui Mo, PhD, David Jarjoura, PhD, Susheela Tridandapani, PhD, Natarajan Muthusamy, DVM, Ph.D, John C. Byrd, MD

Blood (2011) 118 (21): 3717.

https://doi.org/10.1182/blood.V118.21.3717.3717

Published: 2011

Journal Articles

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

Rosa Lapalombella, PhD, Asha Ramanunni, MD, Yuh-Ying Yeh, PhD, Liwen Wang, PhD, Shruti Jha, Justin Staubli, Sarah E. M. Herman, PhD, Leslie A Andritsos, MD, Jeffrey A. Jones, MD, MPH, Joseph M. Flynn, DO, MPH, Xiaokui Mo, PhD, MAS, Amy J. Johnson, PhD, Peter Thompson, MD, Paul A. Algate, PhD, Scott Stromatt, MD, Michael A Freitas, Ph.D., Natarajan Muthusamy, DVM, Ph.D, John C. Byrd, MD

Blood (2011) 118 (21): 622.

https://doi.org/10.1182/blood.V118.21.622.622

Published: 2011

Journal Articles

GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density

Sarwish Rafiq, MA, Carolyn M Cheney, BS, Gerard Lozanski, MD, Rosa Lapalombella, PhD, Xiaokui Mo, PhD, Anthony Siadak, MD, David Jarjoura, PhD, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2010) 116 (21): 1847.

https://doi.org/10.1182/blood.V116.21.1847.1847

Published: 2010

Journal Articles

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

Bo Yu, Yicheng Mao, Li-Yuan Bai, Sarah E.M. Herman, Asha Ramanunni, Yan Jin, Xiaokui Mo, PhD, Carolyn Cheney, Kenneth K. Chan, PhD, David Jarjoura, Guido Marcucci, MD, Robert Lee, L.James Lee, John C. Byrd, MD, Natarajan Muthusamy, DVM, PhD

Blood (2010) 116 (21): 1475.

https://doi.org/10.1182/blood.V116.21.1475.1475

Published: 2010

NARROW

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Protein Phosphatase 2A Activation Dependent Down Regulation of PGC1-Alpha and FOXO1 Phosphorylation with OSU-2S in Human Lymphoma Cells

Par-4 Overexpression Impedes Leukemogenesis in the Eµ-TCL1 Leukemia Model

OSU-2S, a Novel PKC Activator, Mediates PKC Dependent Cell Death, Differentiation and Cell Cycle Arrest in Acute Myeloid Leukemia

CD33 Targeted Immunoliposomal Delivery of OSU-2S, a Non-Immunosuppressive FTY720 Derivative, Mediates Selective Cytotoxicity in Acute Myeloid Leukemia

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia and Lymphoma

SL-401 Mediates Potent Cytotoxicity Against CD123+ AML and MDS with Excess Blasts and Demonstrates Therapeutic Benefit in PDX Model

Leukemic Cell Expressed CTLA-4 Suppresses T Cells Via Down-Modulation of CD80 By Trans-Endocytosis

Effects of the Btk Inhibitor Ibrutinib on Monocyte Responses to Antibodies

BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia

Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia

Aberrant Epigenetic Suppression of the Ptprot Gene Encoding a Protein Tyrosine Phosphatase Targeting KIT in Acute Myeloid Leukemia

A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics

Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties,

Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic Signals

GlycoVariant Anti-CD37 Small Modular Immuno-Pharmaceutical Exhibits Superior Natural Killer Cell Mediated Cytotoxicity Against Chronic Lymphocytic Leukemia Cells at Low Concentrations and Low Antigen Density

Liposomal Targeted Delivery Overcomes Immunostimulatory Effects of Oligonucleotide Based Therapy In Chronic Lymphocytic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only